The results showed that the PD-L1 expression level as reflected by the combined positive score (CPS), which is a comprehensive index incorporating the number of PD-L1-positive tumor cells and tumor-infiltrating immune cells, was significantly correlated with the treatment response to pembrolizumab; however, when only the PD-L1 expression on tumor cells was used as an indicator (tumor proportion score, TPS), no significant association with the clinical efficacy was observed [115]. The gene discussed is CD274; the disease is neoplasm.